Rep. Robert Bresnahan, Jr. Sells Off Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Medpace Holdings, Inc. NASDAQ: MEDP. In a filing disclosed on February 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Medpace stock on January 13th. The trade occurred in the Representative's "JOINT OWNERSHIP LPL ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Lowe's Companies NYSE: LOW on 2/7/2025.
• Purchased $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 2/3/2025.
• Purchased $1,001 - $15,000 in shares of Take-Two Interactive Software NASDAQ: TTWO on 2/3/2025.
• Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 2/3/2025.
• Purchased $1,001 - $15,000 in shares of Alibaba Group NYSE: BABA on 1/30/2025.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 1/30/2025.
• Sold $1,001 - $15,000 in shares of Robinhood Markets NASDAQ: HOOD on 1/29/2025.
• Sold $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 1/29/2025.
• Sold $1,001 - $15,000 in shares of Manhattan Associates NASDAQ: MANH on 1/29/2025.
• Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 1/29/2025.

Medpace Trading Up 1.0 %

NASDAQ MEDP traded up $3.24 during trading hours on Wednesday, hitting $344.01. The company's stock had a trading volume of 353,905 shares, compared to its average volume of 276,818. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The company's 50-day simple moving average is $343.28 and its two-hundred day simple moving average is $347.47. The company has a market capitalization of $10.48 billion, a PE ratio of 27.24, a price-to-earnings-growth ratio of 3.76 and a beta of 1.36.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Medpace

A number of institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in Medpace in the 4th quarter valued at approximately $217,000. Palisades Investment Partners LLC raised its stake in shares of Medpace by 9.2% in the fourth quarter. Palisades Investment Partners LLC now owns 15,919 shares of the company's stock worth $5,289,000 after purchasing an additional 1,338 shares during the last quarter. Novem Group bought a new position in shares of Medpace during the fourth quarter valued at $718,000. Focus Partners Advisor Solutions LLC purchased a new stake in shares of Medpace during the fourth quarter valued at $234,000. Finally, Voloridge Investment Management LLC increased its holdings in Medpace by 55.9% in the 4th quarter. Voloridge Investment Management LLC now owns 164,208 shares of the company's stock worth $54,555,000 after buying an additional 58,861 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Baird R W cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Robert W. Baird upped their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. William Blair reiterated an "outperform" rating on shares of Medpace in a research report on Tuesday, October 22nd. Finally, TD Cowen dropped their price target on Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research note on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $381.44.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.